We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Again Rejects Allergan's Migraine Drug but Approves Eye Treatment
FDA Again Rejects Allergan's Migraine Drug but Approves Eye Treatment
Allergan got bad and good news recently from the FDA, with the agency rejecting for a second time the company's migraine treatment Semprana due to manufacturing issues but approving a new indication for its eye treatment Ozurdex.